Aims An open, controlled, randomized, crossover study was conducted in healthy males to assess the possible occurrence of a pharmacokinetic/pharmacodynamic interaction between warfarin and the selective serotonin re-uptake inhibitor citalopram. Methods Twelve subjects received a single 25 mg dose of racemic warfarin either alone or on Day 15 of a 21-day oral dosing regimen of 40 mg citalopram daily. Blood samples for pharmacokinetic analysis were obtained over a 168 h period after warfarin dosing. The degree of anticoagulation was assessed by the prothrombin time.
Introduction pharmacodynamics of warfarin in healthy subjects. Citalopram is an antidepressant belonging to a class of drugs that selectively and potently inhibit serotonin re-uptake into central neurons [1] . The oral chiral anticoagulant warfarin Methods has been shown to be involved in a number of drug-drug Twelve, healthy male subjects aged between 21 and 32 years interactions resulting in changes in its pharmacokinetics as and weighing between 63 and 90 kg participated in the well as in hypoprothrombinaemic response [2] . (R)-warfarin study, which was approved by the Medeval Independent is approximately 5-8 times less potent an oral anticoagulant Ethics Committee. A complete physical examination as well than (S)-warfarin in humans [3] . Warfarin is eliminated as routine biochemical and haematological tests were almost entirely by hepatic CYP450 enzymes, in a partially performed to ensure that the subjects were medically fit. stereospecific manner. Stereoselective metabolism by
No abnormalities in the haematological tests were accepted the CYP2C9 isozyme leads to the 7-hydroxylation of for study inclusion. Each subject provided his written (S)-warfarin [4, 5] of anticoagulation was assessed by the prothrombin time as described by Quick [9] . Prothrombin times were determined time vs time curve (AUC PT )) between treatment groups were compared using two-way analyses of variance on the daily on the 3 days preceding warfarin administration to determine baseline values and to evaluate whether citalopram log transformed data. ; intraindividual variability (CV)=4.1±2.5%.) indicated that day imprecision was below 8% for both enantiomers. Predose citalopram concentrations were quantified by h.p.l.c. steady-state had been reached. Baseline prothrombin times were not affected by repeated administration of citalopram. based on the method of Øyehaug et al. [6] .
Pharmacokinetic parameters of (S)-and (R)-warfarin The pharmacokinetic [12, 13] and pharmacodynamic [13] outcomes for warfarin in this study are consistent with that were determined by non-compartmental methods [11] . The pharmacokinetic and pharmacodynamic parameters (maximal previously reported. Major drug interactions involving warfarin that result in marked changes in the hypoprothromconcentration (C max ), AUC(0, 168h), oral clearance (CL/F ), apparent volume of distribution (V z /F), maximum probinaemic response in most individuals have been found to arise from changes in the pharmacokinetics of (S)-warfarin thrombin time (R max ) and the area under the prothrombin citalopram does not alter the metabolism of warfarin
